image
Healthcare - Medical - Instruments & Supplies - NASDAQ - BE
$ 6.32
-1.39 %
$ 217 M
Market Cap
-3.25
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NYXH stock under the worst case scenario is HIDDEN Compared to the current market price of 6.32 USD, Nyxoah S.A. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NYXH stock under the base case scenario is HIDDEN Compared to the current market price of 6.32 USD, Nyxoah S.A. is HIDDEN

This DCF valuation model was last updated on May, 7, 2025.

The intrinsic value of one NYXH stock under the best case scenario is HIDDEN Compared to the current market price of 6.32 USD, Nyxoah S.A. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart NYXH

image
$12.0$12.0$11.0$11.0$10.0$10.0$9.0$9.0$8.0$8.0$7.0$7.0$6.0$6.0$5.0$5.015 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '25
FINANCIALS
4.52 M REVENUE
3.98%
-58.8 M OPERATING INCOME
-30.39%
-56.4 M NET INCOME
-26.37%
-49.2 M OPERATING CASH FLOW
-9.93%
-16.3 M INVESTING CASH FLOW
-51.00%
77.4 M FINANCING CASH FLOW
359.36%
1.26 M REVENUE
-0.24%
-18.3 M OPERATING INCOME
-22.24%
-15.1 M NET INCOME
11.66%
-12.2 M OPERATING CASH FLOW
9.25%
-6.58 M INVESTING CASH FLOW
-113.08%
23.4 M FINANCING CASH FLOW
157.35%
Balance Sheet Nyxoah S.A.
image
Current Assets 98.1 M
Cash & Short-Term Investments 85.6 M
Receivables 3.38 M
Other Current Assets 9.15 M
Non-Current Assets 60.3 M
Long-Term Investments 0
PP&E 8.25 M
Other Non-Current Assets 52.1 M
54.01 %5.77 %5.21 %32.87 %Total Assets$158.4m
Current Liabilities 21.5 M
Accounts Payable 3.75 M
Short-Term Debt 1.37 M
Other Current Liabilities 16.4 M
Non-Current Liabilities 23.6 M
Long-Term Debt 21.3 M
Other Non-Current Liabilities 2.34 M
8.30 %3.03 %36.35 %47.15 %5.17 %Total Liabilities$45.2m
EFFICIENCY
Earnings Waterfall Nyxoah S.A.
image
Revenue 4.52 M
Cost Of Revenue 1.55 M
Gross Profit 2.97 M
Operating Expenses 61.8 M
Operating Income -58.8 M
Other Expenses -2.38 M
Net Income -56.4 M
10m10m00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)5m(2m)3m(62m)(59m)2m(56m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
65.67% GROSS MARGIN
65.67%
-1300.80% OPERATING MARGIN
-1300.80%
-1310.24% NET MARGIN
-1310.24%
-52.30% ROE
-52.30%
-37.40% ROA
-37.40%
-44.65% ROIC
-44.65%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Nyxoah S.A.
image
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)2018201820192019202020202021202120222022202320232024202420252025
Net Income -56.4 M
Depreciation & Amortization 764 K
Capital Expenditures -6.07 M
Stock-Based Compensation 0
Change in Working Capital 0
Others 12.3 M
Free Cash Flow -55.3 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Nyxoah S.A.
image
Wall Street analysts predict an average 1-year price target for NYXH of $18.4 , with forecasts ranging from a low of $15 to a high of $27 .
NYXH Lowest Price Target Wall Street Target
15 USD 137.34%
NYXH Average Price Target Wall Street Target
18.4 USD 191.59%
NYXH Highest Price Target Wall Street Target
27 USD 327.22%
Price
Max Price Target
Min Price Target
Average Price Target
3030252520201515101055Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 8
6. Ownership
Insider Ownership Nyxoah S.A.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK , May 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). prnewswire.com - 1 week ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK, May 05, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK, NY / ACCESS Newswire / May 3, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK CITY, NY / ACCESS Newswire / May 2, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK CITY, NY / ACCESS Newswire / May 1, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK CITY, NY / ACCESS Newswire / April 30, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). accessnewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 2 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK , April 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). prnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK, April 25, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Nyxoah S.A. (“Nyxoah” or the “Company”) (NASDAQ: NYXH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. globenewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK CITY, NY / ACCESS Newswire / April 24, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). accessnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK, NY / ACCESS Newswire / April 23, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ:NYXH). accessnewswire.com - 3 weeks ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Nyxoah S.A. - NYXH NEW YORK , April 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Nyxoah S.A. ("Nyxoah" or the "Company") (NASDAQ: NYXH). prnewswire.com - 3 weeks ago
8. Profile Summary

Nyxoah S.A. NYXH

image
COUNTRY BE
INDUSTRY Medical - Instruments & Supplies
MARKET CAP $ 217 M
Dividend Yield 0.00%
Description Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. It offers Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. The company was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Contact Rue Edouard Belin 12, Mont-Saint-Guibert, 1435 https://www.nyxoah.com
IPO Date April 28, 2021
Employees 183
Officers Mr. Jeyakumar Subbaroyan Chief Clinical Officer Mr. Bruno Onkelinx Chief Technical Officer Mr. John Landry Chief Financial Officer Mr. Remi Renard Chief of Staff Mikaela Kirkwood Corporate Communication & Investor Relations Manager Ms. An Moonen General Counsel Mr. Loic Moreau President of International Mr. Robert Taub MBA Co-Founder & Chairman Mr. Olivier Taelman Chief Executive Officer & Executive Director Ms. Maggie McGowan Chief HR Officer